Opens in a new tab
Skip to content
Edx New Montage Example 4

EarlyTect ® Stool DNA Test for Colorectal Cancer Screening

Overview

EarlyTect® is a non-invasive stool DNA test designed to support colorectal cancer screening by detecting abnormal of the SDC2 (Syndecan-2) gene.

The test is intended for use by healthcare professionals as part of a structured colorectal cancer screening or diagnostic pathway.

EarlyTect® offers an alternative option for patients who are unwilling or unable to undergo invasive procedures such as colonoscopy.

What is EarlyTect®?

EarlyTect® is a molecular diagnostic test that analyses stool-derived DNA for abnormal methylation of SDC2 gene, a biomarker associated with colorectal cancer and advanced adenomas.

  • Non-invasive stool sample
  • PCR-based molecular analysis
  • Designed to detect colorectal cancer across disease stages
A diagram shows colon cancer progression from pre cancer to stage IV, with increasing tumour size. Text describes EarlyTect, a non invasive stool DNA test for colorectal cancer screening that detects syndecan 2 methylation, even in asymptomatic cases.

How EarlyTect® Works

1. Stool sample collection
The patient collects a stool sample using a dedicated collection kit.

2. Laboratory analysis
Stool-derived DNA is analysed using a validated molecular assay to assess SDC2 methylation

3. Result Reporting
Results are returned to the requesting clinician to support screening and follow-up decisions.

EarlyTect® does not require bowel preparation, anesthesia, or fasting.

1 2 3

Clinical Performance

Clinical studies have reported:

  • Sensitivity of approximately 90% for colorectal cancer detection
  • Specificity of approximately 90%
  • Consistent detection across cancer stages and tumour locations

EarlyTect® is designed as a screening or adjunctive tool and does not replace colonoscopy, which remains the diagnostic reference standard.

Two arrows display test statistics for the EarlyTect Stool DNA test: an orange arrow shows "Sensitivity 90.2%"—about 9 out of 10 colorectal cancer patients are detected, making it a reliable option for colorectal cancer screening.

Who May Be Considering for Testing

EarlyTect® may be considered for:

  • Individuals undergoing colorectal cancer screening
  • Patients reluctant to undergo colonoscopy
  • Patients requiring an additional non-invasive assessment
  • Clinical pathways where molecular stool testing is appropriate

Availability Through EDX Medical

EarlyTect® is available in the UK Through EDX Medical.

For ordering information, turnaround times, and pathway integration, please contact EDX Medical.

BC95 – Advanced Bowel Cancer Testing Form

EDX Medical Commitment to Patients:

At EDX Medical, we are committed to upholding the highest standards of patient care. Your well-being, safety, and rights are our top priorities in all aspects of our laboratory services.

If you have any information or context that may assist our team in interpreting your test results, or if you wish to discuss, or provide feedback, about any aspect of your testing process, please don’t hesitate to contact us via our contact page. Your input is valued and vital to our mission of delivering safe, reliable, and clinically meaningful laboratory services.


FAQs

No. EarlyTect® is a non-invasive stool DNA test intended to support screening or clinical assessment. Colonoscopy remains the diagnostic reference standard.

EarlyTect® detects abnormal methylation of the SDC2 (Syndecan-2) gene in stool-derived DNA.

No. The test does no require bowel preparation, anaesthesia, or fasting.

EarlyTect® is available to healthcare professionals through EDX Medical.

Positive results should be reviewed by the treating clinician and may lead to further investigations, including colonoscopy.

Ordering Process

1

Requisition form

Please download, complete and return the application form. This product should only be ordered by clinicians or other medical professional.

2

Testing Process

EDX Medical will ship a sample kit to the specified location and physician, along with instructions for sample procurement. Upon completion of the laboratory analysis, EDX Medical will deliver the comprehensive report to the specified physician within a three-week period.

2

Create an account

Please complete and submit the form below. 

Upon receipt of an invoice from EDX Medical, customer should remit payment by bank transfer (personal accounts) or PO (business accounts).

Order Test

Product Request Form
The image shows the "edx medical" logo. "edx" is written in lowercase white letters inside a blue hexagon, with the word "medical" in blue lowercase text to the right of the hexagon.

The Scottish Prostate Cancer Initiative

EDX Medical is launching a new employee health screening service offering a comprehensive range of tests.